|Day Low/High||77.24 / 79.49|
|52 Wk Low/High||62.48 / 96.79|
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
These two firms have successful drugs and could make nice additions for larger companies.
Experts offer their top stock ideas in oncology detection and treatment.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Some interesting statistics on the day: * Bitcoin is trading at $8.240, for a gain of nearly three percent today. * CNN's Fear and Greed Indicator stands at a neutral 49. * Gold is -$17.70, a drop of -1.4%. * Lumber is -$10, a -2.3% decline. * 3M ...
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
Buying's good for the acquirers, which should give other companies ideas.
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
I started the day with an important piece on bonds - at least I hope so. Sell 'em, short 'em! Trade of the Week - long TBT (consistent with above). Well off the opening, at $37.60 now - and that's a good thing. So far, so good. At 230PM yield...
Because there are other things that will take the wind out of your sails.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...
'These companies are all assessing the Trump effect,' Cramer said.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer reacts to the Syria missile strikes and the weaker-than-expected March jobs report.
"I would say that (today) the averages are faring better than the average stock -- on average. If you know what I mean!" -- Kass Diary, Consider this Yogiism! With opening day yesterday and tonite's NCAA final (I like North Carolina in a high sin...
It's pretty normal to have profit-taking after such a strong first quarter.